Statements (51)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
biomarker
nucleic acid molecule |
| gptkbp:advantage |
high specificity
chemical stability high affinity low immunogenicity |
| gptkbp:alternativeTo |
antibodies
|
| gptkbp:approvedBy |
FDA (for Pegaptanib)
|
| gptkbp:binds |
cells
proteins small molecules tissues |
| gptkbp:canBe |
double-stranded
single-stranded modified chemically synthesized engineered for affinity engineered for specificity |
| gptkbp:composedOf |
gptkb:gene
peptides |
| gptkbp:criteria |
gptkb:SELEX
|
| gptkbp:discoveredBy |
gptkb:Ellington_and_Szostak
|
| gptkbp:discoveredIn |
1990
|
| gptkbp:example |
gptkb:Macugen
gptkb:Pegaptanib |
| https://www.w3.org/2000/01/rdf-schema#label |
Aptamers
|
| gptkbp:structure |
secondary structure
tertiary structure |
| gptkbp:usedFor |
gptkb:cancer
gptkb:nanotechnology environmental monitoring food safety testing cell imaging molecular imaging molecular switches biomarker discovery antiviral therapy gene regulation anticoagulant therapy protein purification molecular recognition targeted drug delivery pathogen detection cell sorting therapeutic inhibition toxin detection |
| gptkbp:usedIn |
biosensors
therapeutics diagnostics |
| gptkbp:bfsParent |
gptkb:SomaScan_Assay
|
| gptkbp:bfsLayer |
6
|